PT3500255T - Composições farmacêuticas oftálmicas e utilizações relacionadas com estas - Google Patents

Composições farmacêuticas oftálmicas e utilizações relacionadas com estas

Info

Publication number
PT3500255T
PT3500255T PT178411443T PT17841144T PT3500255T PT 3500255 T PT3500255 T PT 3500255T PT 178411443 T PT178411443 T PT 178411443T PT 17841144 T PT17841144 T PT 17841144T PT 3500255 T PT3500255 T PT 3500255T
Authority
PT
Portugal
Prior art keywords
pharmaceutical compositions
ophthalmic pharmaceutical
uses relating
relating
ophthalmic
Prior art date
Application number
PT178411443T
Other languages
English (en)
Original Assignee
Orasis Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orasis Pharmaceuticals Ltd filed Critical Orasis Pharmaceuticals Ltd
Publication of PT3500255T publication Critical patent/PT3500255T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
PT178411443T 2016-08-19 2017-08-18 Composições farmacêuticas oftálmicas e utilizações relacionadas com estas PT3500255T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662377154P 2016-08-19 2016-08-19

Publications (1)

Publication Number Publication Date
PT3500255T true PT3500255T (pt) 2023-01-10

Family

ID=60935566

Family Applications (1)

Application Number Title Priority Date Filing Date
PT178411443T PT3500255T (pt) 2016-08-19 2017-08-18 Composições farmacêuticas oftálmicas e utilizações relacionadas com estas

Country Status (14)

Country Link
US (5) US9867810B1 (pt)
EP (2) EP3500255B1 (pt)
JP (2) JP7297308B2 (pt)
KR (2) KR102588499B1 (pt)
CN (2) CN116726006A (pt)
AU (2) AU2017311636B2 (pt)
BR (1) BR112019002967A2 (pt)
CA (1) CA3031370A1 (pt)
ES (1) ES2934790T3 (pt)
IL (2) IL297367A (pt)
MX (2) MX2019001877A (pt)
PL (1) PL3500255T3 (pt)
PT (1) PT3500255T (pt)
WO (1) WO2018033792A2 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017311636B2 (en) * 2016-08-19 2023-08-10 Orasis Pharmaceuticals Ltd. Ophthalmic pharmaceutical compositions and uses relating thereto
PL3681500T3 (pl) 2018-04-24 2022-08-01 Allergan, Inc. Zastosowanie chlorowodorku pilokarpiny w leczeniu starczowzroczności
US11077053B2 (en) 2018-08-21 2021-08-03 Allergan, Inc. Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia
WO2020087021A1 (en) * 2018-10-26 2020-04-30 Ocuphire Pharma, Inc. Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders
WO2020226915A1 (en) * 2019-05-08 2020-11-12 Harrow Ip, Llc Pharmaceutical compositions for treating presbyopia and methods for fabricating thereof
MX2020012116A (es) * 2020-11-12 2022-08-09 Cesar Alejandro Sanchez Galeana Composicion oftalmologica sinergica en dosis de baja concentracion eficaz en la prevencion, control y erradicacion de la presbicia.
WO2022169959A1 (en) * 2021-02-04 2022-08-11 Sydnexis, Inc. Ophthalmic compositions for presbyopia
CN115368310A (zh) 2021-05-18 2022-11-22 奥库菲尔医药公司 合成甲磺酸酚妥拉明的方法
WO2023052977A1 (en) * 2021-09-29 2023-04-06 Avaca Pharma Private Limited Compositions, methods and uses thereof
US20230263727A1 (en) * 2022-01-14 2023-08-24 Somerset Therapeutics, Llc Ophthalmologically suitable low pka buffer-containing pilocarpine compositions and related methods
WO2023143575A1 (zh) * 2022-01-29 2023-08-03 南京济群医药科技股份有限公司 一种m-胆碱受体激动剂化合物及其制备方法和用途
US20230248699A1 (en) 2022-02-09 2023-08-10 Somerset Therapeutics, Llc Formulations of pilocarpine and brimonidine compounds and related methods

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4255415A (en) * 1978-11-22 1981-03-10 Schering Corporation Polyvinyl alcohol ophthalmic gel
IT1229075B (it) 1985-04-05 1991-07-17 Fidia Farmaceutici Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico
US4851521A (en) 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
JP2536806B2 (ja) 1991-03-27 1996-09-25 アルコン ラボラトリーズ インコーポレイテッド ゲル化多糖類と微粉砕された薬剤担体とを組み合わせた局部眼科用組成物
US5178635A (en) * 1992-05-04 1993-01-12 Allergan, Inc. Method for determining amount of medication in an implantable device
US5744155A (en) 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
US5422116A (en) 1994-02-18 1995-06-06 Ciba-Geigy Corporation Liquid ophthalmic sustained release delivery system
SE9401108D0 (sv) 1994-03-31 1994-03-31 Leiras Oy Ophthalmic composition I
SE9401109D0 (sv) 1994-03-31 1994-03-31 Leiras Oy Opthalmic composition II
US6309630B1 (en) * 1994-05-24 2001-10-30 Insite Vision Incorporated Non-steroidal anti-inflammatory ophthalmic suspensions
US5698533A (en) 1994-07-26 1997-12-16 Kang; Meng-Che Ophthalmic pharmaceutical composition
US5972326A (en) * 1995-04-18 1999-10-26 Galin; Miles A. Controlled release of pharmaceuticals in the anterior chamber of the eye
US5612027A (en) 1995-04-18 1997-03-18 Galin; Miles A. Controlled release of miotic and mydriatic drugs in the anterior chamber
TW389694B (en) * 1995-08-17 2000-05-11 Novartis Ag Compositions including o-carboxyalkyl chitosan and methods of use in ophthalmics
CA2193149C (en) * 1995-12-22 2002-04-23 David H. Donabedian Cationic therapuetic agents and delivery systems
JP2000506182A (ja) 1996-03-13 2000-05-23 ラボラトワール・メルク・シヤルプ・エ・ドーム―シブレ・エス・エヌ・セー 液―ゲル相転移を起こすタイプの点眼剤組成物
EP0995435B1 (en) 1997-05-14 2007-04-25 Senju Pharmaceutical Co., Ltd. Aqueous suspension preparations with excellent redispersibility
US6265444B1 (en) 1997-05-23 2001-07-24 Insite Vision Incorporated Ophthalmic composition
US6291466B1 (en) 1998-07-30 2001-09-18 Allergan Sales, Inc. Cholinergic agents in the treatment of presbyopia
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
SE0002211D0 (sv) 2000-06-13 2000-06-13 Synphora Ab Methods and compositions for prevention of myopia
JP2004503601A (ja) 2000-07-13 2004-02-05 ファルマシア・コーポレーション 眼のｃｏｘ−２媒介疾患の処置及び予防におけるｃｏｘ−２阻害剤の使用法
PE20020146A1 (es) 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
US6540990B2 (en) 2000-09-22 2003-04-01 Gerard M. Nolan Physiological method of improving vision
US6273092B1 (en) 2000-09-22 2001-08-14 Gerard M. Nolan Methods for treating various eye disorders
US6605640B2 (en) 2001-01-31 2003-08-12 Gerard M. Nolan Method of treating certain eye diseases
US20020160988A1 (en) 2001-02-20 2002-10-31 Israel Institute For Biological Research Compounds co-inducing cholinergic up-regulation and inflammation down-regulation and uses thereof
US20040058926A1 (en) 2001-05-04 2004-03-25 Rebanta Bandyopadhyay Method of using cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders
AR034371A1 (es) 2001-06-08 2004-02-18 Novartis Ag Composiciones farmaceuticas
US20030018382A1 (en) 2001-07-17 2003-01-23 Pflugfelder Stephen C. Process for improving vision
FR2834212B1 (fr) 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
US20050208102A1 (en) 2003-04-09 2005-09-22 Schultz Clyde L Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
CA2839930C (en) 2003-06-13 2016-07-05 Alcon, Inc. Ophthalmic compositions containing a synergistic combination of two polymers
WO2005014046A2 (en) * 2003-08-07 2005-02-17 Allergan, Inc. Compositions for delivery of therapeutics into the eyes and methods for making and using the same
US20050119262A1 (en) 2003-08-21 2005-06-02 Pharmacia Corporation Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
MXPA03011987A (es) 2003-12-19 2005-06-23 Osio Sancho Alberto Metodo para el tratamiento de la presbicia induciendo cambios en el poder y fisiologia corneal.
ATE439123T1 (de) 2004-07-02 2009-08-15 Novagali Pharma Sa Verwendung von emulsionen zur intra- und periocularen injection
WO2006062875A1 (en) 2004-12-08 2006-06-15 Merck & Co., Inc. Ophthalmic nanoparticulate formulation of a cyclooxygenase-2 selective inhibitor
WO2008011836A2 (es) 2006-07-25 2008-01-31 Osmotica Corp. Soluciones oftálmicas
DE602006008643D1 (de) 2006-12-18 2009-10-01 Jorge Luis Benozzi Ophthalmische Zusammensetzungen von parasympathischen Stimulantia und Entzündungshemmer zur Verwendung bei der Behandlung von Presbyopie
JP2010513405A (ja) 2006-12-21 2010-04-30 ノボ・ノルデイスク・エー／エス 二量体プロラクチンレセプターリガンド
CA2676919C (en) 2007-01-31 2013-01-29 Allergan, Inc. Novel biomaterials for ocular drug delivery and a method for making and using same
WO2008130591A2 (en) 2007-04-18 2008-10-30 The Gi Company, Inc. Using trefoil polypeptides to treat eye lesions associated with ophthalmic procedures
CA2687717A1 (en) 2007-05-24 2008-12-18 Aciex Therapeutics, Inc. Formulations and methods for treating dry eye
GB0724558D0 (en) 2007-12-15 2008-01-30 Sharma Anant Optical correction
WO2010135731A1 (en) 2009-05-22 2010-11-25 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
US8299079B2 (en) 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
CN102781452B (zh) 2009-12-23 2014-05-28 阿利梅拉科学公司 减少与皮质类固醇的眼内使用相关的眼压的发生率的方法
CA2849366C (en) 2011-09-20 2019-09-10 Juan Carlos Abad Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism
US10507245B2 (en) * 2012-07-19 2019-12-17 Luis Felipe Vejarano Restrepo Ophthalmic formulation and method for ameliorating presbyopia
US9089562B2 (en) * 2013-08-28 2015-07-28 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
US10064818B2 (en) * 2013-08-28 2018-09-04 Presbyopia Therapies, LLC Compositions and methods for the treatment of presbyopia
ES2538551B1 (es) * 2013-12-20 2016-01-13 Eurocanarias Oftalmológica, Sl Composición Oftálmica para la corrección de la presbicia
US20170007637A1 (en) 2014-02-11 2017-01-12 Orasis Pharmaceuticals Ltd. Pharmacological ophthalmic composition for use in the correction of presbyopia and its administration
AU2017311636B2 (en) * 2016-08-19 2023-08-10 Orasis Pharmaceuticals Ltd. Ophthalmic pharmaceutical compositions and uses relating thereto

Also Published As

Publication number Publication date
MX2023003124A (es) 2023-03-22
AU2017311636B2 (en) 2023-08-10
MX2019001877A (es) 2019-09-13
AU2017311636A1 (en) 2019-02-14
CN109803652A (zh) 2019-05-24
CN116726006A (zh) 2023-09-12
ES2934790T3 (es) 2023-02-27
KR102588499B1 (ko) 2023-10-11
US9867810B1 (en) 2018-01-16
KR20220162876A (ko) 2022-12-08
IL264664A (pt) 2019-03-31
US10639297B2 (en) 2020-05-05
US20180207136A1 (en) 2018-07-26
JP2023105147A (ja) 2023-07-28
CA3031370A1 (en) 2018-02-22
PL3500255T3 (pl) 2023-03-13
RU2019107585A (ru) 2020-09-21
IL264664B2 (en) 2023-03-01
JP7297308B2 (ja) 2023-06-26
EP3500255A4 (en) 2020-03-25
IL297367A (en) 2022-12-01
BR112019002967A2 (pt) 2019-05-14
US20220184039A1 (en) 2022-06-16
JP2019524826A (ja) 2019-09-05
EP3500255A2 (en) 2019-06-26
AU2023226732A1 (en) 2023-09-28
WO2018033792A2 (en) 2018-02-22
RU2019107585A3 (pt) 2020-12-22
EP4190328A1 (en) 2023-06-07
IL264664B (en) 2022-11-01
EP3500255B1 (en) 2022-11-30
US11129812B2 (en) 2021-09-28
KR102472774B1 (ko) 2022-11-30
US20180318264A1 (en) 2018-11-08
KR20190051973A (ko) 2019-05-15
US20200222369A1 (en) 2020-07-16
WO2018033792A3 (en) 2018-03-29

Similar Documents

Publication Publication Date Title
PL3500255T3 (pl) Farmaceutyczne kompozycje okulistyczne i powiązane z nimi zastosowania
HK1259145A1 (zh) 3-脫氧衍生物及其藥物組合物
GB201913962D0 (en) Ophthalmic drug compositions
PT3426226T (pt) Composição oftalmológica
EP3515467C0 (en) OPHTHALMIC COMPOSITION COMPRISING CICLOSPORINE
HK1252026A1 (zh) 藥物組合及其應用
EP3310376A4 (en) MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF
PL3452075T3 (pl) Oftalmiczna kompozycja farmaceutyczna
GB2568579B (en) Ophthalmic drug compositions
GB201608323D0 (en) Pharmaceutical compositions
PT3426294T (pt) Formulação farmacêutica compreendendo anticorpo, ciclodextrina e metionina
IL263040A (en) Pharmaceutical composition comprising eteplirsen
FI3445331T3 (fi) Säilöntäainevapaita farmaseuttisia oftalmisia koostumuksia
IL266537A (en) pharmaceutical preparation
ZA201807851B (en) Pharmaceutical formulation
HK1245113A1 (zh) 藥物組合物及其用途
HUE053974T2 (hu) Szemészeti gyógyászati készítmény
IL254711B (en) History of diazepine-indole and medicinal preparations containing them
GB201611920D0 (en) Pharmaceutical compositions
HUE057830T2 (hu) Famitinib tartalmú gyógyszerkészítmény
ZA201903341B (en) Pharmaceutical compositions and uses thereof
GB201713920D0 (en) Pharmaceutical compositions and uses thereof
GB201604810D0 (en) Pharmaceutical compositions and uses
ZA201602862B (en) Preservative free pharmaceutical ophthalmic compositions
GB201700831D0 (en) Pharmaceutical compositions